



OMICS INTERNATIONAL



OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over **700** leading-edge peer reviewed Open Access Journals and organizes over **1000** International Conferences annually all over the world. OMICS International journals have over **10 million** readers and the fame and success of the same can be attributed to the strong editorial board which contains over **50000** eminent personalities that ensure a rapid, quality and quick review process. OMICS International signed an agreement with more than **1000** International Societies to make healthcare information Open Access.

OMICS Journals are welcoming Submissions

OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS International follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website:

<http://omicsonline.org/Submitmanuscript.php>



Richard J Ablin

Professor


Department of Pathology

University of Arizona College of Medicine




Biography

Open Access



Prior to joining the Arizona Cancer Center and the University of Arizona, College of Medicine as Research Professor of Immunobiology and Pathology . Dr Ablin served consecutively as Director Scientific Investigation at Tetragenex Pharmaceuticals Inc Park Ridge NJ and Director Immunobiology Unit Department of Urology and Research Associate Professor of Urology State University of New York at Stony Brook School of Medicine. He is President of the Robert Benjamin Ablin Foundation for Cancer Research founded in memory of his father since 1979 Dr Ablin received his PhD in Microbiology from the State University of New York at Buffalo in 1967 following which he continued his training in immunology as a United States Public Health Service. Postdoctoral Fellow at the Medical School under the late renowned Distinguished Professor Ernest Witebsky Dr Ablin recently received the degree of DSc honoris causa from Lake Forest College his undergraduate alma mater and was honored as the recipient of the First Award for Scientific Excellence by The Haakon Ragde Foundation for Advanced Cancer Studies in recognition “for his invaluable contribution to humankind and exceptional scientific insight and valiant fight against cancer. Dr Ablin discovered prostatespecific antigen PSA in 1970 for which he was a nominee for the Lasker Award in 1997 His discovery of PSA led to the development of the PSA test A pioneer of cryosurgery and the concept of cryoimmunotherapy for the treatment of cancer Dr Ablin has extensive experience in cancer research particularly in the study of the development and metastasis of cancer A member of Phi Beta Kappa and various professional societies including the American Association for Cancer.



Biography

Research the American Association of Immunologists the British Association of Surgical Oncology the New York Academy of Sciences and Sigma Xi he was a founding member and Vice President 1977-80 of the American College of Cryosurgery and served as President 1977-80 of the International Society of Cryosurgery who named him Honorary LifeTime President in 1980. Dr Ablin is a Diplomat of the American Board of Clinical Immunology and Allergy and certified by the American Academy of Microbiology in Public Health and Medical Laboratory Microbiology Cited in several biographical references including American Men and Women of Science Who's Who of Emerging Leaders in America and Who's Who in the World he has been an invited speaker at numerous national and international scientific meetings and has contributed numerous articles to professional journals and texts. Dr Ablin is coeditor of the book series Cancer Metastasis Biology and Treatment and serves on the editorial board of several journals including Biomarkers in Medicine Cancer Science Current Opinion in Oncology and the Journal of Translational Medicine.



Research Interest

Open Access



Studies are directed toward: a) ascertaining the role of the inter- and/or intratumoural microenvironment (milieu) in contributing to the development and progression of cancer; b) the differentiation of latent (indolent) cancer from one that is aggressive and clinically important and should be treated and c) development of response criteria (biological markers) to evaluate the effectiveness of new therapeutic regimens and/or agents.

For Upcoming Conferences

➤ <http://www.conferenceseries.com/>



OMICS International Open Access Membership

OMICS International Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors.

For more details and benefits, click on the link below:

<http://omicsonline.org/membership.php>

